An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling

Emery G. Dora, Shannan Rossi, Scott Weaver, Sean N. Tucker, Roberto Mateo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.

Original languageEnglish (US)
JournalVaccine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chikungunya virus
Adenoviridae
Neutralizing Antibodies
neutralizing antibodies
Vaccines
vaccines
mice
vaccine development
Adenovirus Vaccines
mosquito-borne diseases
vector vaccines
structural proteins
Culicidae
Inbred C57BL Mouse
Antibody Formation
mouth
animal models
Viruses
viruses
antibodies

Keywords

  • Adenovirus
  • Chikungunya
  • Oral
  • Tablet
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling. / Dora, Emery G.; Rossi, Shannan; Weaver, Scott; Tucker, Sean N.; Mateo, Roberto.

In: Vaccine, 01.01.2019.

Research output: Contribution to journalArticle

@article{7c59092053c8428cae0a664724ecc547,
title = "An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling",
abstract = "Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La R{\'e}union CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.",
keywords = "Adenovirus, Chikungunya, Oral, Tablet, Vaccine",
author = "Dora, {Emery G.} and Shannan Rossi and Scott Weaver and Tucker, {Sean N.} and Roberto Mateo",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2019.04.069",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling

AU - Dora, Emery G.

AU - Rossi, Shannan

AU - Weaver, Scott

AU - Tucker, Sean N.

AU - Mateo, Roberto

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.

AB - Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.

KW - Adenovirus

KW - Chikungunya

KW - Oral

KW - Tablet

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85064836650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064836650&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.04.069

DO - 10.1016/j.vaccine.2019.04.069

M3 - Article

C2 - 31047675

AN - SCOPUS:85064836650

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -